Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition

International Journal of Oncology

Volumn 35, Issue 4, 2009, Pages 789-796

  Buchholz, Stefan ^a,b,c   Seitz, Stephan ^a,b,c   Schally, Andrew V ^a,b   Engel, Jörg B ^d   Rick, Ferenc G ^a,b   Szalontay, Luca ^a,b   Hohla, Florian ^a,b,e   Krishan, Awtar ^b   Papadia, Andrea ^f   Gaiser, Timo ^g   Brockhoff, Gero ^c   Ortmann, Olaf ^c   Diedrich, Klaus ^h   Köster, Frank ^h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

^f UNIVERSITY OF MIAMI   (United States)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Cell cycle analysis; LHRH antagonist; LHRH receptor; Triple negative breast cancer; Xenografted mouse model

Indexed keywords

CETRORELIX; D 20762; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GONADORELIN; GONADORELIN RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, ESTROGEN; RECEPTORS, LHRH; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70449359173     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000391     Document Type: Article

References (37)

1. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007. (Pubitemid 46698581)
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007. (Pubitemid 47219710)
3. Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728, 2007. (Pubitemid 46668532)
4. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K and Mitchell EP: Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 110: 876-884, 2007. (Pubitemid 47257667)
5. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF and Ellis IO: Prognostic markers in triple-negative breast cancer. Cancer 109: 25-32, 2007. (Pubitemid 46120191)
6. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24: 5652-5657, 2006. (Pubitemid 46631305)
7. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO and Foulkes WD: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134, 2007. (Pubitemid 47272190)
8. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD and Schally AV: High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53: 5439-5446, 1993. (Pubitemid 23342164)
9. Emons G and Schally AV: The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 9: 1364-1379, 1994. (Pubitemid 24224014)
10. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD and Schally AV: High affinity binding and direct anti-proliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77: 1458-1464, 1993. (Pubitemid 24000896)
11. Bajusz S, Csernus VJ, Janaky T, Bokser L, Fekete M and Schally AV: New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 32: 425-435, 1988. (Pubitemid 19042048)
12. Szepeshazi K, Schally AV and Halmos G: LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int J Oncol 30: 1485-1492, 2007.
13. Halmos G, Schally AV and Kahan Z: Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix. Int J Oncol 17: 367-373, 2000.
14. Limonta P, Pratesi G, Moretti RM, Montagnani Marelli M, Motta M and Dondi D: Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II, Jungwirth et al, Eur J Cancer 1997, 33(7), 1141-1148.
15. Eur J Cancer 34: 1134-1136, 1998.
16. Schally AV and Comaru-Schally AM: Hypothalamic and other peptide hormones. In: Cancer Medicine. Vol.52(14). 5th edition. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF and Frei E (eds.) BC Dekker Publishers, Hamilton, pp802-816, 2006.
17. Wormald PJ, Eidne KA and Millar RP: Gonadotropin-releasing hormone receptors in human pituitary: ligand structural requirements, molecular size, and cationic effects. J Clin Endocrinol Metab 61: 1190-1194, 1985.
18. Engel JB and Schally AV: Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3: 157-167, 2007. (Pubitemid 46146968)
19. Schally AV: Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20: 1247-1262, 1999. (Pubitemid 29512447)
20. Dondi D, Festuccia C, Piccolella M, Bologna M and Motta M: GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep 15: 393-400, 2006.
21. Emons G and Schulz KD: Primary and salvage therapy with LH-RH analogues in ovarian cancer. Recent Results Cancer Res 153: 83-94, 2000.
22. Sharoni Y, Bosin E, Miinster A, Levy J and Schally AV: Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 86: 1648-1651, 1989. (Pubitemid 19078959)
23. Kahan Z, Nagy A, Schally AV, Halmos G, Arencibia JM and Groot K: Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Res Treat 59: 255-262, 2000. (Pubitemid 30243047)
24. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM and Schally AV: Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat 21: 35-45, 1992.
25. Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT Jr, LeRoith D, Schally AV and Sharoni Y: Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. J Clin Endocrinol Metab 77: 963-968, 1993. (Pubitemid 23301471)
26. Segal-Abramson T, Kitroser H, Levy J, Schally AV and Sharoni Y: Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci USA 89: 2336-2339, 1992.
27. Bajo AM, Schally AV, Halmos G and Nagy A: Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin Cancer Res 9: 3742-3748, 2003. (Pubitemid 37169243)
28. Eidne KA, Flanagan CA, Harris NS and Millar RP: Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64: 425-432, 1987.
29. Pinski J, Yano T, Miller G and Schally AV: Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75. Prostate 20: 213-224, 1992.
30. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
31. Krishan A: Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66: 188-193, 1975.
32. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX and Stern HM: A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878-5887, 2008.
33. Tang X, Yano T, Osuga Y, Matsumi H, Yano N, Xu J, Wada O, Koga K, Kugu K, Tsutsumi O, Schally AV and Taketani Y: Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. J Clin Endocrinol Metab 87: 3721-3727, 2002. (Pubitemid 34879518)
34. Fekete M, Wittliff JL and Schally AV: Characteristics and distribution of receptors for [D-TRP6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 3: 137-147, 1989. (Pubitemid 20199263)
35. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P, Kavanagh J, Steger M, Schulz KD and Emons G: Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol 90: 552-559, 2003.
36. Engel JB, Griesinger G, Schultze-Mosgau A, Felberbaum R and Diedrich K: GnRH agonists and antagonists in assisted reproduction: pregnancy rate. Reprod Biomed Online 13: 84-87, 2006. (Pubitemid 44054849)
37. Engel JB, Audebert A, Frydman R, Zivny J and Diedrich K: Presurgical short term treatment of uterine fibroids with different doses of cetrorelix acetate: a double-blind, placebo-controlled multicenter study. Eur J Obstet Gynecol Reprod Biol 134: 225-232, 2007. (Pubitemid 47470003)